Janney Montgomery Scott LLC Purchases 5,753 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janney Montgomery Scott LLC increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 40.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,806 shares of the medical equipment provider's stock after purchasing an additional 5,753 shares during the quarter. Janney Montgomery Scott LLC's holdings in Lantheus were worth $1,772,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the 3rd quarter worth $25,000. Signaturefd LLC raised its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC boosted its position in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after buying an additional 146 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new position in Lantheus in the 3rd quarter worth approximately $51,000. Institutional investors own 99.06% of the company's stock.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.10% of the stock is owned by company insiders.

Lantheus Trading Down 1.5 %

Shares of Lantheus stock traded down $1.36 during trading hours on Wednesday, hitting $90.44. 708,707 shares of the company were exchanged, compared to its average volume of 769,730. Lantheus Holdings, Inc. has a 1 year low of $53.47 and a 1 year high of $126.89. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of 15.05 and a beta of 0.44. The business has a 50-day moving average of $92.07 and a 200-day moving average of $99.16.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent research reports. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. JMP Securities reissued a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial reissued a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.